



SAFETY DATA SHEET

Revision date 15-Jun-2025

Version 4

Page 1 / 14

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Lymphocyte immune globulin, anti-thymocyte globulin (equine) sterile solution

Product Code(s) ATGAM

Trade Name: ATGAM

Item Code H000035424,H000200183,H000200184,H000400473,H000439300

Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as immunosuppressive agent

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
66 Hudson Boulevard East
New York, New York 10001
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements

Signal word Not classified

Hazard statements Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 2 / 14

Version 4

(see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 0.5%≤C<2% Skin Corr. 1A :: C≥5% Skin Corr. 1B :: 2%≤C<5% Skin Irrit. 2 :: 0.5%≤C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7 (017-002-00-2) (017-002-01-X)	Press. Gas Skin Corr. 1A (H314) Acute Tox. 3 (H331)	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25% STOT SE 3 :: C≥10%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Lymphocyte immune globulin, anti-thymocyte globulin (equine) (CAS #: NOT)	5		Not Listed	Not classified	Not classified	No data available	No data available

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 3 / 14

Version 4

ASSIGNED)							
Glycine (CAS #: 56-40-6)	*		200-272-2	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Glycine 56-40-6	7930	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

+ Substance with a Union workplace exposure limit

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
--	--

4.3. Indication of any immediate medical attention and special treatment needed

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 4 / 14

Version 4

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Prevent inhalation, contact with eye, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 5 / 14

Version 4

atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Glycine

Latvia TWA: 5 mg/m³;
Russia MAC: 5 mg/m³

Sodium hydroxide

ACGIH OEL (Ceiling) 2 mg/m³
ACGIH TLV Ceiling: 2 mg/m³
Austria TWA-TMW: 2 mg/m³; inhalable fraction
STEL-KZGW: 4 mg/m³ (8 X 5 min); inhalable fraction
Bulgaria TWA: 2.0 mg/m³; alkaline aerosols
Czech Republic 1 mg/m³
Ceiling: 2 mg/m³
Denmark Ceiling: 2 mg/m³;
Estonia TWA: 1 mg/m³;
STEL: 2 mg/m³;
Finland Ceiling: 2 mg/m³;
France 2 mg/m³
Hungary TWA-AK: 1 mg/m³;
STEL-CK: 2 mg/m³;
STEL: 2 mg/m³;
Ireland 2 mg/m³
Ceiling Limit Value
Latvia TWA: 0.5 mg/m³;
Poland TWA-NDS: 0.5 mg/m³;
STEL-NDSCh: 1 mg/m³;
Romania TWA: 1 mg/m³;
STEL: 3 mg/m³;
Slovakia TWA: 2 mg/m³;
Spain STEL (VLA-EC): 2 mg/m³;
Switzerland TWA-MAK: 2 mg/m³; inhalable dust
STEL-KZGW: 2 mg/m³; inhalable dust
OSHA PEL TWA: 2 mg/m³
(vacated) Ceiling: 2 mg/m³
STEL: 2 mg/m³;

+ Hydrochloric Acid

ACGIH OEL (Ceiling) 2 ppm
ACGIH TLV Ceiling: 2 ppm
Austria TWA-TMW: 5 ppm;
TWA-TMW: 8 mg/m³;
STEL-KZGW: 10 ppm (8 X 5 min);

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 6 / 14

Version 4

Bulgaria	STEL-KZGW: 15 mg/m ³ (8 X 5 min); TWA: 5 ppm; TWA: 8.0 mg/m ³ ; STEL: 10 ppm; STEL: 15.0 mg/m ³ ; 8 mg/m ³
Czech Republic	Ceiling: 15 mg/m ³
Denmark	STEL: 5 ppm; STEL: 8 mg/m ³ ;
Estonia	TWA: 5 ppm; TWA: 8 mg/m ³ ; STEL: 10 ppm; STEL: 15 mg/m ³ ;
European Union	TWA: 5 ppm; TWA: 8 mg/m ³ ; STEL: 10 ppm; STEL: 15 mg/m ³ ;
Finland	STEL: 5 ppm; STEL: 7.6 mg/m ³ ;
Germany DFG	TWA-MAK: 2 ppm; I(2); TWA-MAK: 3.0 mg/m ³ ; I(2); Peak: 4 ppm; Peak: 6 mg/m ³ ;
Germany TRGS	TWA-AGW; 2 ppm (exposure factor 2); TWA-AGW; 3 mg/m ³ (exposure factor 2);
Hungary	TWA-AK: 8 mg/m ³ ; TWA-AK: 5 ppm; STEL-CK: 165 mg/m ³ ; STEL-CK: 10 ppm;
Ireland	TWA: 8 mg/m ³ ; TWA: 5 ppm; STEL: 10 ppm; STEL: 15 mg/m ³ ;
Italy MDLPS	TWA: 5 ppm; TWA: 8 mg/m ³ ; STEL: 10 ppm; STEL: 15 mg/m ³ ;
Ceiling Limit Value	2 ppm 3.0 mg/m ³
Latvia	TWA: 5 ppm; TWA: 8 mg/m ³ ; STEL: 10 ppm; STEL: 15 mg/m ³ ;
Netherlands	TWA: 5 ppm; TWA: 8 mg/m ³ ; STEL: 10 ppm; STEL: 15 mg/m ³ ;
Poland	TWA-NDS: 5 mg/m ³ ; STEL-NDSch: 10 mg/m ³ ;
Romania	TWA: 5 ppm; TWA: 8 mg/m ³ ; STEL: 10 ppm; STEL: 15 mg/m ³ ;
Russia	MAC: 5 mg/m ³
Slovakia	TWA: 5 ppm; TWA: 8.0 mg/m ³ ; Ceiling: 15 mg/m ³ ;

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 7 / 14

Version 4

Spain	TWA-(VLA-ED): 5 ppm; TWA-(VLA-ED): 7.6 mg/m ³ ; STEL (VLA-EC): 10 ppm; STEL (VLA-EC): 15 mg/m ³ ;
Switzerland	TWA-MAK: 2 ppm; TWA-MAK: 3 mg/m ³ ; STEL-KZGW: 4 ppm; STEL-KZGW: 6 mg/m ³ ;
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m ³
OSHA PEL	Ceiling: 5 ppm Ceiling: 7 mg/m ³ (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m ³
United Kingdom	TWA: 1 ppm; gas and aerosol mist TWA: 2 mg/m ³ ; gas and aerosol mist STEL: 5 ppm; gas and aerosol mist STEL: 8 mg/m ³ ; gas and aerosol mist

Pfizer Occupational Exposure Band (OEB) Statement: The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake (ADI) range, based on available hazard data with appropriate safety factors applied. Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of the band.

Lymphocyte immune globulin, anti-thymocyte globulin (equine)

Pfizer Occupational Exposure Band (OEB): B-OEB 1 (control exposure to the range of $\geq 10000 \mu\text{g/day}$)

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Wear impervious gloves (e.g. Nitrile, etc.) as minimum protection. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Wear impervious protective clothing when handling this compound. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 8 / 14

Version 4

Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

Thermal hazards No information available.

Environmental exposure controls No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	Sterile solution
Physical state	Liquid
Color	Pink to Brown
Odor	No information available.
Odor threshold	No information available

Property	Values
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	No data available
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	Soluble Water
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 9 / 14

Version 4

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term May cause irritation skin, eye (based on components). May produce allergic reactions after systemic administration.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include fever, chills, skin reaction, blood cell changes, systemic toxicity. Serious allergic reactions, including anaphylaxis, have been reported.

Acute toxicity Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation Based on available data, the classification criteria are not met.

Skin corrosion/irritation Based on available data, the classification criteria are not met.

Respiratory or skin sensitization Based on available data, the classification criteria are not met.

STOT - single exposure Based on available data, the classification criteria are not met.

STOT - repeated exposure Based on available data, the classification criteria are not met.

Reproductive toxicity Based on available data, the classification criteria are not met.

Germ cell mutagenicity Based on available data, the classification criteria are not met.

Carcinogenicity Based on available data, the classification criteria are not met.

Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Glycine	= 7930 mg/kg (Rat)	-	-
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 10 / 14

Version 4

--	--	--	--

Irritation / Sensitization: (Study Type, Species, Severity)

+ Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Lymphocyte immune globulin, anti-thymocyte globulin (equine)

14 Day(s) Monkey Intravenous 40 mg/kg/day NOAEL No effects at maximum dose

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Lymphocyte immune globulin, anti-thymocyte globulin (equine)

Embryo / Fetal Development Monkey Intravenous 10 mg/kg/day NOAEL Fetotoxicity, Not Teratogenic

Reproductive & Fertility Monkey Intravenous 40 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Lymphocyte immune globulin, anti-thymocyte globulin (equine)

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

In Vitro Chromosome Aberration Lymphocytes Human Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Micronucleus Rat Negative

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

+ Hydrochloric Acid

IARC

Group 3

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects

No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties of the formulation have not been thoroughly investigated.
Releases to the environment should be avoided.

12.1. Toxicity

No information available

12.2. Persistence and degradability

Persistence and degradability

No information available.

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 11 / 14

Version 4

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Glycine	Not PBT/vPvB
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 12 / 14

Version 4

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Lymphocyte immune globulin, anti-thymocyte globulin (equine)

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed

Glycine

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-272-2
AICS	Present

Sodium hydroxide

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

+ Hydrochloric Acid

CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

Switzerland

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 13 / 14

Version 4

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable
Storage of Hazardous Material Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable
Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide 1310-73-2	75	-
+ Hydrochloric Acid 7647-01-0	75	-

Persistent Organic Pollutants

Not applicable

Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid 7647-01-0	25	250

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Biocidal Products Regulation (EU) No 528/2012 (BPR)

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
+ Hydrochloric Acid 7647-01-0	Product-type 2: Disinfectants and algicides not intended for direct application to humans or animals

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

SAFETY DATA SHEET

Product Name Lymphocyte immune globulin, anti-thymocyte globulin
(equine) sterile solution
Revision date 15-Jun-2025

Page 14 / 14

Version 4

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage. H331 - Toxic if inhaled.

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Reason for revision SDS review

Revision date 15-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.